背景:缺乏关于类固醇难治性急性移植物抗宿主病(SR-aGvHD)患者健康相关生活质量(HRQoL)的证据。评估HRQoL是HOVON113MSC试验的次要目标。在这里,我们描述了EQ-5D-5L的结果,EORTCQLQ-C30和FACT-BMT适用于所有在基线时完成这些问卷的成年患者(即,治疗开始前;n=26)。
方法:使用描述性统计来描述基线患者和疾病特征,EQ-5D维度得分和值,EQVAS评分,EORTCQLQ-C30量表/项目和汇总评分,FACT-BMT分量表和总分。
结果:平均EQ-5D值为0.36。总的来说,96%的患者报告了日常活动的问题,92%有疼痛/不适,84%的流动性,80%有自我保健,72%患有焦虑/抑郁。EORTCQLQ-C30总分均值为43.50。功能量表的平均量表/项目得分范围为21.79至60.00,症状量表从39.74到75.21,单个项目从5.33到91.67。平均FACT-BMT总分为75.31。平均子量表得分从身体健康的10.09到社会/家庭幸福感的23.94不等。
结论:我们的研究表明SR-aGvHD患者的HRQoL较差。改善这些患者的HRQoL和症状管理应该是当务之急。
BACKGROUND: Evidence regarding health-related quality of life (HRQoL) in patients with steroid-refractory acute graft-versus-host disease (SR-aGvHD) is lacking. Evaluating HRQoL was a secondary objective of the HOVON 113 MSC trial. Here we describe the outcomes of the EQ-5D-5L, EORTC QLQ-C30, and FACT-BMT for all adult patients who completed these questionnaires at baseline (i.e., before the start of treatment; n = 26).
METHODS: Descriptive statistics were used to describe baseline patient and disease characteristics, EQ-5D dimension scores and values, EQ VAS scores, EORTC QLQ-C30 scale/item and summary scores, and FACT-BMT subscale and total scores.
RESULTS: The mean EQ-5D value was 0.36. In total, 96% of the patients reported problems with usual activities, 92% with pain/discomfort, 84% with mobility, 80% with self-care, and 72% with anxiety/depression. The mean EORTC QLQ-C30 summary score was 43.50. Mean scale/item scores ranged from 21.79 to 60.00 for functioning scales, from 39.74 to 75.21 for symptom scales, and from 5.33 to 91.67 for single items. The mean FACT-BMT total score was 75.31. Mean subscale scores ranged from 10.09 for physical well-being to 23.94 for social/family well-being.
CONCLUSIONS: Our study showed that HRQoL in patients with SR-aGvHD is poor. Improving HRQoL and symptom management in these patients should be a top priority.